CN112924608A - Polypeptide marker for early diagnosis of diabetes, detection kit and method - Google Patents
Polypeptide marker for early diagnosis of diabetes, detection kit and method Download PDFInfo
- Publication number
- CN112924608A CN112924608A CN201911238679.7A CN201911238679A CN112924608A CN 112924608 A CN112924608 A CN 112924608A CN 201911238679 A CN201911238679 A CN 201911238679A CN 112924608 A CN112924608 A CN 112924608A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- standard
- solution
- kit
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Abstract
The invention relates to the field of medical biological detection, in particular to a new application of a polypeptide marker in preparing a diabetes diagnosis reagent or a kit. The invention provides a method and a kit for quantitatively detecting endogenous polypeptide in serum by utilizing liquid chromatography-mass spectrometry Multiple Reaction Monitoring (MRM). The content of a polypeptide marker GVLSSRQLGLPGPPDVPDHAA in human serum is quantitatively determined by the reagent and the method, and then a marker variable and a determined intercept point value are calculated based on a binary logistic regression equation for early warning and/or diagnosis of diabetes. The kit and the detection method have the advantages of good stability, high specificity and potential for clinical popularization.
Description
Technical Field
The invention relates to the field of medical biological detection technology and diagnosis, prevention and treatment of metabolic diseases, in particular to a method for quantitatively determining human plasma endogenous polypeptide, a kit and a method for preparing early warning and/or diagnosis of diabetes by using a polypeptide marker.
Background
According to 2017, international diabetes union data show that there are 4.15 hundred million diabetics all over the world, wherein type 2diabetes (T2 DM) accounts for more than 95%. The global diabetes population is expected to increase to 5.52 hundred million by 2030. Diabetes mellitus is the 3 rd largest disease that endangers human health following cardiovascular diseases and tumors. At present, although the diagnostic standard of type 2diabetes is clear and has gold standards such as Oral Glucose Tolerance Test (OGTT), the diabetes has no obvious symptoms in the initial stage and has long latent period, so that the disease condition is irreversible and the optimal intervention period is missed when the symptoms appear or the intervention treatment is carried out after clinical diagnosis is confirmed, and the finding of the biomarker for early warning and diagnosis has important significance for researching the pathology, classification, early diagnosis, delaying and preventing the occurrence of the diabetes.
The discovery of new diagnostic markers using multigroup chemistry techniques is a hot spot in current research. The polypeptide plays an important role in the pathogenesis and intervention treatment of diabetes, such as peptide preparations of various polypeptide drugs, such as glucagon-like peptide-1 (GLP-1) analogues, dolaglutide (dulaglutide), Brain Natriuretic Peptide (BNP) and the like. The polypeptide can embody the processes of synthesis, processing and degradation of protein under different physiological and pathological conditions, and has a regulating effect on the processes of gene expression, substance metabolism and the like, so that the polypeptide omics technology is adopted to discover the novel polypeptide biomarker for early warning/diagnosis of diabetes mellitus, and the polypeptide biomarker has great potential.
And (3) marker verification: the currently discovered type 2diabetes potential biomarkers include gene variation, RNA transcripts, polypeptides, proteins, lipids, small molecule metabolites (branched chain amino acids/aromatic amino acids) and the like, but mostly come from complication samples, such as diabetic nephropathy, diabetes accompanied with hypertension and hyperglycemia samples, gestational diabetes and the like (Chinese patent CN 106645757A; medical reviews, 2019, (20), 4080-; in addition, after the differential markers are screened by adopting a multigroup chemical technology, further clinical sample verification work is lacked, so that the clinical application value is limited; or ELISA or Western blot verification is adopted, the experiment cost is high, and the flux is insufficient (Chinese patent CN 108957011; chromatogram, 2019, 37 (8): 853-.
Based on the problems in the research, the invention adopts a method of combining non-targeted peptidomics and targeted quantitative peptidomics, and the method has the characteristics of high flux, good data repeatability and high sensitivity. The method comprises the steps of screening potential diagnostic markers by adopting a strategy from discovery to verification, successfully screening and verifying endogenous polypeptide markers in human serum from pre-diabetic clinical samples (without complications), wherein the endogenous polypeptide markers can be used for early warning and/or diagnosis of diabetes, the diagnostic sensitivity and specificity of the markers are good, and a kit for quantitatively determining the content of target polypeptides and for early warning and/or diagnosis of diabetes is prepared, and the kit is not reported at present.
Disclosure of Invention
The invention aims to solve the problems of shortage of early warning and diagnosis markers of diabetes, low sensitivity, low specificity and the like, adopts the strategies of discovering differential polypeptide by non-targeted polypeptide omics and verifying targeted polypeptide omics, provides an application of a polypeptide marker in early warning/diagnosis of diabetes and a kit thereof, and also provides a method for quantitative analysis and detection of the polypeptide marker.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
(1) non-targeted analysis is carried out on endogenous polypeptides in serum of normal people, patients with early diabetes and patients with diabetes (without complications such as hypertension, hyperlipidemia and the like) by adopting a non-targeted proteomics method, differential polypeptides are screened by a non-standard quantitative method, screening conditions comprise a P value, a credible confidence interval and the like, and the differential polypeptides meeting the conditions are reserved.
(2) And (2) the differential polypeptide in the step (1) is verified in another batch of healthy human/diabetic patient (without complications such as hypertension, hyperlipidemia and the like) clinical samples by synthesizing a standard peptide and a dimethyl marker and adopting a targeted polypeptide omics method. And the stability of the polypeptide is considered, and the potential of the polypeptide for preparing and developing a diabetes early warning/diagnosis kit is preliminarily evaluated.
(3) And (3) adopting SPSS statistical software, performing binary logistic regression analysis to obtain regression as a marker variable, and adopting an ROC (receiver operating characteristic) curve to evaluate the sensitivity and specificity of the marker.
(4) Use of markers: the content of the polypeptide GVLSSRQLGLPGPPDVPDHAA is significantly changed in diabetic patients. The binary logistic regression equation is:
X＝-8.710+14.766×C(GVLSSRQLGLPGPPDVPDHAA)
prob (diabetes) 1/[1+ e-X]
Wherein C represents the concentration of plasma polypeptide GVLSSRQLGLPGPPDVPDHAA; e is the Euler number, the base of the natural logarithm function; prob is the variable value of the combined marker, when the P value is more than or equal to 0.55, the patient is diagnosed as diabetic, otherwise, the patient is non-diabetic.
(5) The diagnostic system comprises means for: the chromatographic column and the detecting instrument are a liquid chromatogram-mass spectrometer.
(6) Determining the composition of the kit, wherein the kit comprises seven reagents or solutions of A, B, C, D, E, F and G, and specifically comprises the following steps:
dimethyl labeling reagent: a, PBS buffer (pH 8.0-8.4); b, formaldehyde at a concentration of 4% by volume (light standard treatment agent) and/or deuterated formaldehyde at a concentration of 4% by volume (medium standard treatment agent); c,0.6M sodium cyanoborohydride (NaBH3 CN); d, ammonia water with the mass concentration of 1%; e, 5% by volume formic acid solution;
standard solution F: the polypeptide GVLSSRQLGLPGPPDVPDHAA is treated by a dimethyl light standard reagent to obtain a light standard solution, and the light standard solution is dissolved in formic acid with the volume concentration of 0.1-1% after being dried, desalted and dried again, and the final concentration of the polypeptide is 10-40 mug/mL respectively;
internal standard solution G containing stable isotope: the polypeptide GVLSSRQLGLPGPPDVPDHAA is processed by a dimethyl labeling bid-winning reagent to obtain a bid-winning solution, and the solution is dissolved in formic acid with the volume concentration of 0.1-1% after drying, desalting and drying again, wherein the final concentration of the polypeptide is 0.3-10 mug/mL respectively.
The method comprises the following specific steps:
1) and (3) ultrafiltration: taking 10-50 mu L of plasma sample, and centrifuging by a 10K Da ultrafiltration tube to extract endogenous polypeptide; drying to obtain an endogenous polypeptide sample;
2) light mark marking: sequentially treating the endogenous polypeptide sample by using the dimethyl-labeled light standard reagent A, B, C, D, E to obtain an endogenous polypeptide dimethyl-labeled sample (light standard), and drying;
3) desalting: desalting with TIP head or solid phase extraction column filled with C18, and drying; refrigerating in a refrigerator at minus 80 ℃ for standby;
4) preparing a test solution: dissolving the endogenous polypeptide light marker sample with 10-50 μ L of 0.1% -1% formic acid solution, centrifuging at 20000G for 5-8 min, collecting supernatant 10-40 μ L, and adding 10-40 μ L of internal standard solution G to obtain the sample solution to be tested;
5) preparation of a standard curve: diluting the standard solution F with 0.1-1% formic acid solution to obtain a series of standard solutions, taking 1-10 μ L of the standard solution, adding 10-40 μ L of blank plasma sample and 10-40 μ L of internal standard solution G to obtain a series of standard curve samples, wherein the final concentration range is 5ng/mL-1000 ng/mL; wherein the blank plasma sample is obtained by sequentially treating the endogenous polypeptide extracted by ultrafiltration with A, D, E, desalting, drying and dissolving in 0.1-1% formic acid solution; measuring the intensities of light standard and medium-winning ion peaks of the polypeptide by adopting liquid chromatography-mass spectrometry multiple reaction monitoring (LC-MS/MRM), and fitting a standard curve according to the comparison of the peak areas of the light standard and the medium-winning ion peaks;
6) polypeptide content determination: and respectively analyzing the prepared standard curve sample and the clinical sample test solution by adopting LC-MS/MRM, and calculating the content of the target polypeptide by an external standard method.
(7) Conditions of instrumental analysis
The operating conditions of the liquid chromatography are as follows: waters UPLC liquid chromatograph, chromatography column, Acquity UPLC @ HSS, T3,1.8 μm; mobile phase, acetonitrile-0.1% formic acid (a), 0.1% aqueous formic acid (B).
The gradient conditions were as follows:
TABLE 1 liquid chromatography conditions
The mass spectrometry conditions, the Qtrap 5500 mass spectrometer, the mass spectrometry Multiple Reaction Monitoring (MRM), the MRM quantitative ion pair of the target polypeptide and the mass spectrometry parameters are shown in Table 2, and the mass spectrogram is shown in FIG. 1.
TABLE 2 quantitative ion pairs of target polypeptides
(7) Serum samples were used to test the efficacy of the invention. Normal persons were well differentiated from diabetic patients using the combination markers, as shown in fig. 2, which had AUC values of 0.796, sensitivity of 0.78, and specificity of 0.78. The optimum critical point (cut-off) was 0.55. Diabetes is diagnosed as having a value greater than or equal to the cut-off point value.
(8) Stability study of polypeptide markers: the polypeptide related to the patent can be stored for 2 months in a refrigerator at 4 ℃, and no matter a light standard sample or a successful bid sample is obviously degraded, so that the kit is proved to have good stability.
The invention has the advantages that:
1) the process of discovering the biomarker comprises three processes of screening differential polypeptides by adopting a non-targeted metabonomics method, further verifying a structure by polypeptide synthesis and verifying clinical samples of different batches by adopting a targeted quantitative polypeptinomics method of mass spectrum Multiple Reaction Monitoring (MRM), and has higher clinical reference value and reliability.
2) The invention provides a kit for early warning/diagnosis of diabetes, which can be used for conveniently realizing accurate quantitative determination of target polypeptide in a clinical sample to be detected, further calculating a marker variable Prob and a judgment cut-off value (cut-off) by using a binary logistic regression equation, and judging the risk and diagnosis of diabetes of the sample to be detected. The kit has the characteristics of good stability, high diagnosis specificity and high sensitivity, is applied to auxiliary early diagnosis, and has higher development and application values.
Drawings
FIG. 1 MRM detection map of the polypeptide
FIG. 2ROC diagnostic model; drawing notes: area under the AUC curve; sensitivity, specificity, criterion cut-off cutoff
Detailed Description
The following examples are provided to illustrate specific embodiments of the present invention. These examples are illustrative only and do not limit the scope of the present invention in any way. Modifications and substitutions in detail and form may be made to the technical solution of the present invention without departing from the spirit and scope of the present invention, but the modifications and substitutions are within the scope of the present invention.
Example 1: screening of differential polypeptides by non-standard quantitative method
Clinical samples: 23 human serum samples (including 7 healthy person serum samples, 7 pre-diabetic patient serum samples, and 9 type 2 diabetic patient serum samples) were obtained from the sixth national hospital of Shanghai. The patients with pre-diabetes and type 2diabetes are diagnosed or excluded by experts, and the age, Body Mass Index (BMI), blood sugar and other indexes of the three groups of tested people are matched. Blood samples were approved by the local hospital ethics committee and all subjects signed informed consent. Blood samples were collected and stored in a-80 ℃ freezer.
Extracting endogenous polypeptide in serum: an ultrafiltration centrifugal method is adopted. The specific operation flow is as follows: blood samples were taken from-80 ℃ freezer and thawed in ice bath, vortexed, mixed, centrifuged at 20000g for 5min and lipid discarded. mu.L of each serum sample was taken, 125. mu.L of deionized water was added and the mixture was boiled for 5min for denaturation. After cooling to room temperature, 150 μ L of an aqueous solution of 40% acetonitrile-0.1% formic acid by volume was added, vortexed, mixed well and allowed to stand in an ice bath for 40 min. The sample was then transferred to an ultrafiltration tube with a molecular weight cut-off of 10kDa, centrifuged at 6000g at 4 ℃ for 20min and the filter cake was washed twice with 300. mu.L of an aqueous solution of 20% acetonitrile-0.1% formic acid by volume. Collecting filtrate, freeze drying, desalting, and storing in-80 deg.C refrigerator for use. Before sample injection analysis, the sample is redissolved in 25 mu L FA solution with volume concentration of 0.1%, vortexed and mixed uniformly for 2min, 20000g, centrifuged at 4 ℃ for 5min, and the supernatant is taken for nano-LC-MS/MS analysis.
LC-MS/MS data acquisition: a Nano-RPLC-MS/MS system comprising high performance liquid chromatography with quaternary gradient pump (Ultimate 3000), autosampler and linear ion trap-static orbital trap (LTQ-Orbitrap), trap column (3cm × 200 μm, C18); analytical column (12 cm. times.150. mu.m, C18). Mobile phase composition: phase A is 0.1% formic acid solution in water, and phase B is 80% acetonitrile solution containing 0.1% formic acid. The separation gradient was set as: 0-2% B for 10 min; 2-5% of B for 3 min; 5-28% of B, 60 min; 28-45% of B, 15 min; 45-95% B for 1 min; 95% B, 5 min. The flow rate was 0.5. mu.L/min. Mass spectrum conditions: the temperature of the LTQ ion transmission tube was set at 275 deg.C and the electrospray voltage was set at 2.7 kV. All data acquisition modes are data-dependent modes (DDA), mass spectrum full scan is acquired in Orbitrap, scan range is 200-. Secondary mass spectrometry scans were acquired in LTQ using Collision Induced Dissociation (CID) fragmentation. The Xcalibur software (version 2.1, Thermo corporation) was used for system control and data collection.
Mass spectrum data retrieval and analysis: the mass spectrometry data were subjected to data retrieval using Mascot software, and the database was retrieved as a human source library (UniProt, about 17 ten thousand proteins). The search parameters are set as: methionine residue (+15.9949Da) was variably modified without cleavage, with a parent ion mass error of 20ppm and a secondary fragment ion error of 0.8 Da. The polypeptide screening threshold was set at a score above 20 and a false positive rate (FDR) of less than 1%. Polypeptide quantification data analysis was performed using MaxQuant software. The false positive rate (FDR) was 0.01.
Screening the differential polypeptides, wherein 163 differential polypeptides are screened. Further select 21 of the more fold-difference changes for further clinical sample validation, the difference polypeptide information is shown in table 3:
TABLE 3 Difference polypeptide information to further validate
| Polypeptide sequence | Multiple of difference | MW | No. | PI | GRAVY |
| GKSSSYSKQFTSSTSYNRGDSTFES | Adjusted up 2 times | 2738.82 | 25 | 8.43 | -1.34 |
| GVLSSRQLGLPGPPDVPDHAAYHPF | PRE 3-fold up | 2627.94 | 25 | 5.98 | -0.292 |
| SSYSKQFTSSTSYNRGDSTFES | PRE, T2D Down-regulated by a factor of 4-5 | 2466.51 | 22 | 5.79 | -1.286 |
| SYKMADEAGSEADHEGTHSTKR | PRE downregulation by a factor of 5 | 2407.51 | 22 | 5.37 | -1.582 |
| GVLSSRQLGLPGPPDVPDHAA | 2.4 times of PRE Up-regulation | 2083.33 | 21 | 5.21 | -0.19 |
| FTSSTSYNRGDSTFESKS | 3-fold downregulation of T2D | 2001.05 | 18 | 6.07 | -1.217 |
| DQEQSQVAEKPMEGESR | PRE Down-regulated by 3-fold | 1948.05 | 17 | 4.25 | -1.888 |
| GLGHGHEQQHGLGHGHKF | 2-fold Up-Regulation of PRE and 11-fold Down-Regulation of T2D | 1933.08 | 18 | 7.16 | -1.244 |
| HKSEVAHRFKDLGEEN | T2D Up-regulated by 3 times | 1896.05 | 16 | 6.03 | -1.55 |
| SSSYSKQFTSSTSYNRG | PRE Down-regulated by 3-fold | 1886.95 | 17 | 9.7 | -1.329 |
| EALHNHYTQKSLSLSPG | T2D Up-regulated by 5 times | 1882.06 | 17 | 7.01 | -0.824 |
| SSKITHRIHWESASLL | PRE is down-regulated by a factor of 2 and T2D is up-regulated by a factor of 2 | 1865.12 | 16 | 8.51 | -0.294 |
| GLPGPPDVPDHAAYHPF | PRE 3-fold up | 1786.96 | 17 | 5.05 | -0.535 |
| SKITHRIHWESASLL | T2D Down-regulated by 2.8-3.8 fold | 1778.04 | 15 | 8.51 | -0.26 |
| SEETKENEGFTVTAEG | PRE 3-fold up | 1727.76 | 16 | 3.98 | -1.238 |
| SRQLGLPGPPDVPDHAA | 3-fold downregulation of T2D | 1726.91 | 17 | 5.19 | -0.635 |
| GVEVHNAKTKPREEQ | T2D Up-regulated by 3 times | 1721.89 | 15 | 6.76 | -1.7 |
| DIQMTQSPSSVSASVGD | T2D Up-regulated by 3 times | 1708.81 | 17 | 3.56 | -0.241 |
| DEAGSEADHEGTH | PRE Down-regulated by 3-fold | 1354.27 | 13 | 4.17 | -1.738 |
| GVNDNEEGFF | T2D Up-regulated by 3 times | 1127.13 | 10 | 3.57 | -0.85 |
| GSEMVVAGKLQ | T2D Down-regulated by 5-fold | 1118.31 | 11 | 6 | 0.309 |
Note: the expression of up-regulation and down-regulation means that the ratio of the content of the polypeptide in the PRE group (initial diabetes group) or the T2D group (diabetes group) to the content of the corresponding polypeptide in the control group is up-regulation when the ratio is more than 1; down regulation is less than 1.
Example 2: dimethyl-tagged polypeptides and targeted MRM validation
Clinical samples: 18 human serum samples (including 9 serum samples from healthy subjects and 9 serum samples from type 2 diabetic patients) were obtained from the sixth national hospital of Shanghai. The patients with type 2diabetes are diagnosed or excluded by experts, and the indexes of the age, the Body Mass Index (BMI), the blood sugar and the like of the three groups of tested people are matched. The diabetic patients have no complications such as hypertension, hyperglycemia and the like. Blood samples were approved by the local hospital ethics committee and all subjects signed informed consent. Blood samples were collected and stored in a-80 ℃ freezer.
Extracting endogenous polypeptide in serum: reference is made to example 1.
Polypeptide synthesis: based on the information in Table 3 above, the synthetic target peptides were reconfirmed by comparing their MS patterns.
Dimethyl labeling: the following kit is adopted to prepare a winning bid internal standard solution and prepare a standard curve sample and a clinical sample test solution. The kit comprises the following components:
dimethyl labeling reagent: a, PBS buffer (PH 8.0); b, formaldehyde at a concentration of 4% by volume (light standard treatment agent) and/or deuterated formaldehyde at a concentration of 4% by volume (medium standard treatment agent); c,0.6M sodium cyanoborohydride (NaBH3 CN); d, ammonia water with the mass concentration of 1%; e, 5% by volume formic acid solution;
standard solution F: the polypeptide GVLSSRQLGLPGPPDVPDHAA is treated by a dimethyl light standard reagent to obtain a light standard solution, and the light standard solution is dissolved in formic acid with the volume concentration of 0.1 percent after being dried, desalted and dried again, and the final concentration of the polypeptide is respectively 30 mug/mL;
internal standard solution G containing stable isotope: the polypeptide GVLSSRQLGLPGPPDVPDHAA is processed by a dimethyl labeling bid-winning reagent to obtain a bid-winning solution, and the solution is dissolved in formic acid with the volume concentration of 0.1% after being dried, desalted and dried again, and the final concentration of the polypeptide is 0.8 mu g/mL respectively.
The method comprises the following specific steps:
1) and (3) ultrafiltration: taking 25 mu L of plasma sample, and centrifuging by a 10K Da ultrafiltration tube to extract endogenous polypeptide; drying to obtain an endogenous polypeptide sample;
2) light mark marking: sequentially treating the endogenous polypeptide sample by using the dimethyl-labeled light standard reagent A, B, C, D, E to obtain an endogenous polypeptide dimethyl-labeled sample (light standard), and drying;
3) desalting: desalting with TIP head or solid phase extraction column filled with C18, and drying; refrigerating in a refrigerator at minus 80 ℃ for standby;
4) preparing a test solution: back dissolving the endogenous polypeptide light label marker sample by 30 mu L of 0.1% formic acid solution, centrifuging for 8 minutes at 20000G, taking 20 mu L of supernatant, and adding 10 mu L of internal standard solution G to obtain a test solution to be detected;
5) preparation of a standard curve: diluting the standard substance solution F with 0.1% formic acid solution to obtain a series of standard substance solutions, taking 5 μ L of the standard substance solution, adding 40 μ L of blank plasma sample and 10 μ L of internal standard solution G to obtain a series of standard curve samples, wherein the final concentration ranges are 5ng/mL, 50ng/mL, 100ng/mL, 500ng/mL and 1000 ng/mL; wherein the blank plasma sample is obtained by sequentially treating the endogenous polypeptide extracted by ultrafiltration with A, D, E, desalting, drying, and dissolving in 0.1% formic acid solution; measuring the intensities of light standard and medium-winning ion peaks of the polypeptide by adopting liquid chromatography-mass spectrometry multiple reaction monitoring (LC-MS/MRM), and fitting a standard curve according to the comparison of the peak areas of the light standard and the medium-winning ion peaks;
6) polypeptide content determination: and respectively analyzing the prepared standard curve sample and the clinical sample test solution by adopting LC-MS/MRM, and calculating the content of the target polypeptide by an external standard method.
Conditions of instrumental analysis
The operating conditions of the liquid chromatography are as follows: waters UPLC liquid chromatograph, chromatography column, Acquity UPLC @ HSS, T3,1.8 μm; mobile phase, acetonitrile-0.1% formic acid (a), 0.1% aqueous formic acid (B). Gradient conditions are shown in table 1.
The mass spectrometry conditions, Qtrap 5500 mass spectrometer, mass spectrometry Multiple Reaction Monitoring (MRM), and the MRM qualitative and quantitative ion pairs and mass spectrometry parameters of the target 21 polypeptides are shown in table 4.
Qualitative and quantitative ion pairs of table 421 polypeptides
Note: l represents a light bid and M represents a medium bid.
Target verification: the quantitative results show that the polypeptide GVLSSRQLGLPGPPDVPDHAA has obvious difference in normal human and diabetes samples, and can be used for a variable regression diagnosis model. Thereby further optimizing the quantitative ion pair of the target polypeptide as shown in table 2.
Evaluation of stability: the stability of the target polypeptide is further evaluated, and the result shows that the target polypeptide is not obviously degraded after being placed in a refrigerator at 4 ℃ for 2 months, and has the potential for diagnosis markers.
Example 3: determination of early warning/diagnostic markers
From the above quantitative results, it was found that the content of the polypeptide GVLSSRQLGLPGPPDVPDHAA was significantly changed in both the samples of healthy persons and diabetic patients.
And (3) returning the target polypeptide to a marker variable by adopting SPSS statistical software through binary logistic regression analysis, and evaluating the sensitivity and specificity of the combined marker by adopting an ROC (receiver operating characteristic) curve.
The target polypeptide regresses to a marker variable X, and the binary logistic regression equation is:
X＝-8.710+14.766×C(GVLSSRQLGLPGPPDVPDHAA)
prob (diabetes) 1/[1+ e-X]
Wherein C represents the concentration of endogenous polypeptide GVLSSRQLGLPGPPDVPDHAA; e is the Euler number, the base of the natural logarithm function; wherein Prob is the variable value of the combined marker, and the optimal critical point (cut-off) is 0.55. A patient is diagnosed as diabetic if the cut-off point value is greater than or equal to the cut-off point value, otherwise, the patient is non-diabetic.
The cutoff value is determined by working characteristic curve (ROC curve) of the testee according to the P value of the combined marker variable, and taking the P value with the maximum sum of sensitivity and specificity as the optimal cutoff value.
Serum samples were used to test the efficacy of the invention. Normal persons were well differentiated from diabetic patients using the combination markers, as shown in fig. 2, which had AUC values of 0.796, sensitivity of 0.78, and specificity of 0.78. The diagnosis model of the invention has better clinical application effect.
Claims (6)
1. Application of the polypeptide marker GVLSSRQLGLPGPPDVPDHAA in preparation of diabetes early warning and/or diagnosis reagents or kits.
2. The use of the polypeptide combination marker of claim 1 in the preparation of a diabetes early warning/diagnosis reagent or kit, wherein the diagnosis reagent or kit detects the content of polypeptide GVLSSRQLGLPGPPDVPDHAA in serum.
3. Use of a combination marker according to claim 1 for the preparation of a kit for diagnosing a diabetic patient in a subject, wherein the diagnostic reagent or kit is a combination of reagents for detecting the amount of polypeptide GVLSSRQLGLPGPPDVPDHAA using liquid chromatography-mass spectrometry.
4. A test kit for early warning/diagnosis of diabetes, wherein the diagnosis or kit comprises:
(1) dimethyl labeling reagent: a, PBS buffer (pH 8.0-8.4); b, formaldehyde at a concentration of 4% by volume (light standard treatment agent) and/or deuterated formaldehyde at a concentration of 4% by volume (medium standard treatment agent); c,0.6M sodium cyanoborohydride (NaBH3 CN); d, ammonia water with the mass concentration of 1%; e, 5% by volume formic acid solution;
(2) standard solution F: the polypeptide GVLSSRQLGLPGPPDVPDHAA is treated by a dimethyl light standard reagent to obtain a light standard solution, and the light standard solution is dissolved in formic acid with the volume concentration of 0.1-1% after being dried, desalted and dried again, and the final concentration of the polypeptide is 10-40 mug/mL respectively;
(3) internal standard solution G containing stable isotope: the polypeptide GVLSSRQLGLPGPPDVPDHAA is processed by a dimethyl labeling bid-winning reagent to obtain a bid-winning solution, and the solution is dissolved in formic acid with the volume concentration of 0.1-1% after drying, desalting and drying again, wherein the final concentration of the polypeptide is 0.3-10 mug/mL respectively.
5. A method for detecting polypeptide GVLSSRQLGLPGPPDVPDHAA in serum by using the detection kit of claim 4, comprising the following steps:
(1) and (3) ultrafiltration: taking 10-50 mu L of plasma sample, and centrifuging by a 10K Da ultrafiltration tube to extract endogenous polypeptide; drying to obtain an endogenous polypeptide sample;
(2) light mark marking: sequentially treating the endogenous polypeptide sample by using the dimethyl-labeled light standard reagent A, B, C, D, E to obtain an endogenous polypeptide dimethyl-labeled sample (light standard), and drying;
(3) desalting: desalting with TIP head or solid phase extraction column filled with C18, and drying; refrigerating in a refrigerator at minus 80 ℃ for standby;
(4) preparing a test solution: dissolving the endogenous polypeptide light marker sample with 10-50 μ L of 0.1% -1% formic acid solution, centrifuging at 20000G for 5-8 min, collecting supernatant 10-40 μ L, and adding 10-40 μ L of internal standard solution G to obtain the sample solution to be tested;
(5) preparation of a standard curve: diluting the standard solution F with 0.1-1% formic acid solution to obtain a series of standard solutions, taking 1-10 μ L of the standard solution, adding 10-40 μ L of blank plasma sample and 10-40 μ L of internal standard solution G to obtain a series of standard curve samples, wherein the final concentration range is 5ng/mL-1000 ng/mL; wherein the blank plasma sample is obtained by sequentially treating the endogenous polypeptide extracted by ultrafiltration with A, D, E, desalting, drying and dissolving in 0.1-1% formic acid solution; measuring the intensities of light standard and medium-winning ion peaks of the polypeptide by adopting liquid chromatography-mass spectrometry multiple reaction monitoring (LC-MS/MRM), and fitting a standard curve according to the comparison of the peak areas of the light standard and the medium-winning ion peaks;
(6) polypeptide content determination: and respectively analyzing the prepared standard curve sample and the clinical sample test solution by adopting LC-MS/MRM, and calculating the content of the target polypeptide by an external standard method.
6. Use of a combination marker according to claim 1 for the preparation of a kit for diagnosing a diabetic patient in a subject, wherein the combination marker variables and cut-off values are used for early diagnosis and warning of diabetes; the content of the endogenous polypeptide marker in human serum can be quantitatively determined, and then the combined marker variable and the determined intercept value are calculated based on a binary logistic regression equation for early warning and/or diagnosis of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238679.7A CN112924608A (en) | 2019-12-06 | 2019-12-06 | Polypeptide marker for early diagnosis of diabetes, detection kit and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238679.7A CN112924608A (en) | 2019-12-06 | 2019-12-06 | Polypeptide marker for early diagnosis of diabetes, detection kit and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112924608A true CN112924608A (en) | 2021-06-08 |
Family
ID=76162342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911238679.7A Pending CN112924608A (en) | 2019-12-06 | 2019-12-06 | Polypeptide marker for early diagnosis of diabetes, detection kit and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112924608A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264823A (en) * | 2021-12-07 | 2022-04-01 | 浙江大学 | Oligopeptide recognized by serum metabonomics and application thereof |
| CN115792205A (en) * | 2022-09-06 | 2023-03-14 | 华东理工大学 | Method and kit for diagnosing MIDD |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104777242A (en) * | 2014-01-14 | 2015-07-15 | 中国科学院大连化学物理研究所 | Combined markers, kit and system for diagnosis of polycystic ovarian syndrome |
| CN105092753A (en) * | 2014-05-20 | 2015-11-25 | 中国科学院大连化学物理研究所 | Application of combination amine metabolism marker and kit and detection method thereof |
| CN105092842A (en) * | 2014-05-15 | 2015-11-25 | 中国科学院大连化学物理研究所 | Combined metabolic markers for diagnosis of liver cancer and detection kit thereof |
| CN108344830A (en) * | 2017-01-22 | 2018-07-31 | 中国科学院大连化学物理研究所 | Urine sample composite marker object and detection kit and method for diagnosis of prostate cancer |
| CN109682909A (en) * | 2017-10-18 | 2019-04-26 | 中国科学院大连化学物理研究所 | A kind of serum combination marker and its detection kit for evaluating the gliclazide applicability of diabetes B |
| CN109709220A (en) * | 2017-10-25 | 2019-05-03 | 中国科学院大连化学物理研究所 | It is a kind of for the joint marker and kit of diagnosing bladder cancer and application |
-
2019
- 2019-12-06 CN CN201911238679.7A patent/CN112924608A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104777242A (en) * | 2014-01-14 | 2015-07-15 | 中国科学院大连化学物理研究所 | Combined markers, kit and system for diagnosis of polycystic ovarian syndrome |
| CN105092842A (en) * | 2014-05-15 | 2015-11-25 | 中国科学院大连化学物理研究所 | Combined metabolic markers for diagnosis of liver cancer and detection kit thereof |
| CN105092753A (en) * | 2014-05-20 | 2015-11-25 | 中国科学院大连化学物理研究所 | Application of combination amine metabolism marker and kit and detection method thereof |
| CN108344830A (en) * | 2017-01-22 | 2018-07-31 | 中国科学院大连化学物理研究所 | Urine sample composite marker object and detection kit and method for diagnosis of prostate cancer |
| CN109682909A (en) * | 2017-10-18 | 2019-04-26 | 中国科学院大连化学物理研究所 | A kind of serum combination marker and its detection kit for evaluating the gliclazide applicability of diabetes B |
| CN109709220A (en) * | 2017-10-25 | 2019-05-03 | 中国科学院大连化学物理研究所 | It is a kind of for the joint marker and kit of diagnosing bladder cancer and application |
Non-Patent Citations (2)
| Title |
|---|
| SHI-SHU YANG 等: "Enrichment of Phosphorylated Peptides with Metal-Organic Framework Nanosheets for Serum Profiling of Diabetes and Phosphoproteomics Analysis", 《ANALYTICAL CHEMISTRY》 * |
| 牛欢 等: "2型糖尿病临床血清样本的内源性多肽定量组学分析", 《色谱》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114264823A (en) * | 2021-12-07 | 2022-04-01 | 浙江大学 | Oligopeptide recognized by serum metabonomics and application thereof |
| CN114264823B (en) * | 2021-12-07 | 2023-10-13 | 浙江大学 | Serum metabonomics-identified oligopeptides and uses thereof |
| CN115792205A (en) * | 2022-09-06 | 2023-03-14 | 华东理工大学 | Method and kit for diagnosing MIDD |
| WO2024051646A1 (en) * | 2022-09-06 | 2024-03-14 | 华东理工大学 | Method and kit for diagnosing midd |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2005189B1 (en) | MEANS AND METHOD FOR DIAGNOSING DIABETES type II | |
| AU2011209431B2 (en) | Means and methods for diagnosing heart failure in a subject | |
| US20050272095A1 (en) | Methods of identifying biomarkers | |
| CN114373510B (en) | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | |
| EP3470513A1 (en) | Srm assay to indicate cancer therapy | |
| EP3647788A1 (en) | Biomarker for detecting colorectal cancer | |
| CN112858551A (en) | Application of combined metabolic biomarker for diagnosing esophageal squamous carcinoma and kit | |
| Pietrowska et al. | LC-MS-based metabolic fingerprinting of aqueous humor | |
| CN112924608A (en) | Polypeptide marker for early diagnosis of diabetes, detection kit and method | |
| CN112305121A (en) | Application of metabolic marker in atherosclerotic cerebral infarction | |
| CN111521828A (en) | Application of RSPH9 as diagnosis marker or therapeutic target of oligoasthenospermia | |
| CN112924689B (en) | Diabetes diagnosis kit based on quantitative determination of polypeptide combined marker and method thereof | |
| CN112924692B (en) | Diabetes diagnosis kit based on polypeptide quantitative determination and method thereof | |
| KR20160146102A (en) | Diagnostic method for colon cancer using N- glycan mass spectrometry | |
| CN112924687B (en) | Diabetes diagnosis kit based on polypeptide combined marker and method thereof | |
| CN112924691B (en) | Polypeptide combination marker for early diagnosis of diabetes, detection kit and method | |
| CN112924690B (en) | Serum polypeptide combined marker for early warning and/or diagnosis of diabetes, detection kit and method | |
| CN112924688B (en) | Application of polypeptide combined marker in diabetes diagnosis, kit and method thereof | |
| US20170074888A1 (en) | Method for identifying and quantifying carboxyethyl valine modified haemoglobin | |
| CN112630344B (en) | Use of metabolic markers in cerebral infarction | |
| EP3358347B1 (en) | Marker for determining diabetic nephropathy | |
| CN113866285A (en) | Biomarker for diabetes diagnosis and application thereof | |
| CN112858552A (en) | Combined metabolic biomarker and kit for diagnosing esophageal epithelial atypical hyperplasia | |
| CN117147737B (en) | Plasma combined marker for esophageal squamous carcinoma diagnosis, kit and detection method | |
| CN113252806B (en) | Use of S-adenosyl homocysteine in the preparation of a product for the diagnosis or treatment of Kawasaki disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210608 |
|
| RJ01 | Rejection of invention patent application after publication |